Mobile

This study is designed to assess the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior lines of therap...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001052-39

This study is designed to assess the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior lines of therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Co-primary: • Compare progression-free survival (PFS) in patients treated with carfilzomib + filanesib and single-agent carfilzomib • Compare objective response rates (ORR) in patients with low serum alpha 1-acid glycoprotein (AAG) levels at Baseline treated with carfilzomib + filanesib and single-agent carfilzomib

Critère d'inclusion

  • Multiple myeloma

Liens